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Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles loaded with lamivudine and coated with bovine serum albumin (BSA) were 
prepared via a double emulsion method. The influences of experiments parameters such as volume of inner aqueous phase, con-
centration of organic phase and ultrasonication time on the particle size and drug entrapment efficiency were investigated, obtain-
ing PLGA particles with a diameter of ~260 nm and drug entrapment efficiency of ~35%. The particles were observed by scan-
ning electron microscopy and transmittance electron microscopy, showing a core-shell structure. BCA assay found that 58 mg 
BSA was present on/in 1 g LPB particles. The loaded lamivudine showed a burst release at beginning and sustained release until 
24 h in physiological conditions. Low pH could accelerate the release of lamivudine from PLGA particles, making the PLGA 
particles potential intelligent intracellular drug carriers. The PLGA particles were readily internalized into the human liver cells 
within a short time and increased gradually with the prolongation of incubation time regardless of the loading of lamivudine. The 
particles either resided within lysosomes or transferred to cytoplasm, but could not enter into the cell nucleus. The cell viability 
was not significantly influenced in the presence of the particles regardless of lamivudine encapsulation, suggesting that this kind 
of particles may be a good candidate for the intracellular anti-hepatitis B drug delivery. 
PLGA, lamivudine, cell uptake, intracellular distribution, drug delivery 
 





Hepatitis B caused by hepatitis B virus (HBV) is an infec-
tious inflammatory illness of the liver, and is also consid-
ered as a causative factor of the development of hepatocel-
lular carcinoma [1]. HBV infection is one of the most common 
infections over the world and especially severe in China. Of 
the 350–400 million individuals worldwide infected with 
the HBV, one-third resides in China, and about 5% of them 
are chronically infected [2,3]. Every year, estimated 300000 
people die from HBV-related diseases in China, including 
180000 patients with hepatocellular carcinoma. 
Currently, medications for treatment of hepatitis B infec-
tion are mainly divided into antiviral drugs (nucleoside an-
alogues) and immune system modulators (interferon). Alt-
hough none of these drugs can clear the infection, they can 
stop the virus from replicating, thus minimizing liver dam-
age. Among the antiviral drugs, lamivudine (LAM, Figure 
1(a)), a cytosine nucleoside analogue, has shown good re-
sults in the treatment of HBV infection in human beings 
[4,5]. Once phosphorylated to active metabolites, lamivu-
dine can inhibit the HBV reverse transcriptase enzyme 
competitively and act as a chain terminator of DNA synthesis. 
However, this drug exhibits very short physiological 
half-life, and therefore, requires a specially designed dosage 
everyday, which may cause high level resistance and other 
side effects [6]. Thus, protection in physiological environ-
ment and increase of residence time of lamivudine inside 
cells would greatly improve the treatment efficiency. To 
achieve this aim, lamivudine has been encapsulated into 
various colloidal carriers such as biodegradable polymer 
spheres [7] and micelles [8], and conjugated to polysaccharide  
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Figure 1  (a) Chemical structure of lamivudine; (b) preparation process of LPB particles. 
and dendrimers [9,10].  
Poly(lactide-co-glycolide) (PLGA) nanoparticles are widely 
used as carriers for drug, gene and vaccine delivery because 
of its good biocompatibility and biodegradability, low cy-
totoxicity and easy preparation [11,12]. The PLGA particles 
may protect the drug, gene and vaccine against degradation 
and ensure their transport and delivery [13,14], and also can 
control the release rate and achieve targeting [15–18]. Among 
the method for preparation of PLGA particles, the emul-
sification-solvent evaporation is the most frequently em-
ployed one [19]. The water/oil/water (W/O/W) double emul-
sion technique has been successfully developed and used to 
incorporate hydrophilic molecules such as hydrophilic drugs, 
proteins and nucleotide into the lumen of biodegradable 
particles [20–23].  
In our previous study, PLGA particles are used to encap-
sulate hydrophobic dyes and anti-cancer drug by oil/water 
emulsion employing bovine serum albumin (BSA) as stabi-
lizers, which are simultaneously loaded onto the particles dur-
ing the formulation process. The surface immobilized mac-
romolecules enable further covalent grafting of poly(eth-      
ylene glycol) (PEG) and folic acid (FA), or physical modi-
fication via layer-by-layer (LBL) assembly [24–26]. Herein 
we shall use W/O/W double emulsion to encapsulate water 
soluble lamivudine with BSA as macromolecular surfactant. 
The preparation parameters are optimized with respect to the 
particle size and drug encapsulation efficiency. The physio-
chemical properties of resultant particles (the so-called LAM- 
PLGA-BSA, LPB) are characterized in terms of chemical 
composition, morphology, surface charge property and drug 
release kinetics. Finally, cellular uptake kinetics and intra-
cellular distribution of the LPB particles by human liver 
cells and their influences on the cell viability shall be explored. 
1  Materials and methods 
1.1  Reagents 
Poly(lactide-co-glycolide) (PLGA, LA:GA=75:25, MW= 
130 kD), bovine serum albumin (BSA) and 4,6-diamidino- 
2-phenylindole (DAPI) were obtained from Sigma-Aldrich. 
MitoTracker® Green and LysoTracker® Green were pur-
chased from Invitrogen Co., Ltd. All other chemicals were 
analytical grade and used without further treatment. Milli-Q 
water was used throughout the experiments.  
1.2  Particles preparation  
PLGA particles were prepared by means of a double emul-
sion-solvent evaporation method (Figure 1(b)). Briefly, 0.1– 
0.4 mL lamivudine (Figure 1(a)) aqueous solution (10 mg/mL, 
internal aqueous phase) or pure water (blank PLGA/BSA 
particles) was emulsified in 1 mL PLGA dichloromethane 
solution (oil phase) using an ultrasonicator (MISONIX Ul-
trasonic liquid Processors) for desired time (10–120 s). The 
power of ultrasonic was set as 6 W. Four different PLGA 
concentrations (2%, 4%, 6%, 8%; w/v) were employed in 
the oil phase. This primary W/O emulsion was rapidly add-
ed into 4 mL 3% (w/v) BSA aqueous solution (external 
aqueous phase) and emulsified again for the same time pe-
riod. The resultant double emulsion was then poured into 50 
mL Milli-Q water, stirred for 1 h at room temperature to 
allow evaporation of the organic solvent. The PLGA parti-
cles were collected by centrifugation at 15000 r/min for 15 
min, washed with Milli-Q water for three times, and freeze- 
dried overnight under vacuum. PLGA particles containing 
Nile red or coumarin were similarly prepared by addition of 
0.2 mg/mL Nile red or coumarin into PLGA solution before 
mixing with lamivudine solution.  
1.3  Particles characterization  
(1) Morphology. The morphology of the PLGA particles 
was analyzed by scanning electron microscopy (SEM, 
HITACHI S-520) and transmission electron microscopy 
(TEM, Philips TECNAL-10). A drop of the PLGA particles 
suspension was added onto a clean glass and copper grid 
with carbon membrane for SEM and TEM observation,  
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respectively. 
(2) Size and surface charge measurements. The size and 
surface charge of the particles were determined using Beck-
man DelsaTM Nano (Beckman Coulter). The data was aver-
aged from three parallel experiments. 
(3) BSA content assay. To determine the BSA amount on 
the particles, a certain amount PLGA particles was dis-
solved in a solution of 5% (w/v) sodium dodecyl sulfate 
(SDS) in NaOH (pH 13). The system was sonicated at 40°C 
for 40 min and centrifuged at 15000 r/min for 15 min. The 
amount of BSA was measured from the supernatant by a 
BCA protein assay kit. 
(4) Drug loading determination. The drug content was 
determined by a high-pressure liquid chromatography 
(HPLC) method. Briefly, a certain amount of particles was 
dissolved in 1 mol/L NaOH solution, and the suspension 
was stirred at 40°C for 30 min until complete dissolution of 
the polymer spheres. The resultant transparent solution was 
neutralized with 1 mol/L HCl and diluted to a certain vol-
ume. Then the solution was filtered and injected into the 
HPLC equipment to determine drug content. Samples were 
passing through a C18 pre-column and a Jupiter C18 re-
verse-phase (150×3.9 mm (I.D.)) with 5 mm packing parti-
cles (Phenomenex, Torrance, CA). The mobile phase was 
0.02 mol/L phosphate buffer saline (pH 7.2), acetonitrile 
and methanol (91:0.1:8.9). The mobile phase was degassed 
and filtered before use. Flow rate was set at 1.5 mL/min and 
the UV-vis detector was set at 274 nm. The 20 L sample 
was injected and the measurement was repeated in triplicate 
and averaged.  
In this study, drug loading (DL) and entrapment effi-
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(5) Release of lamivudine from the LPB particles [28,29]. 
The release behavior of lamivudine encapsulated inside the 
LPB particles was studied at 37°C. Briefly, 50 mg LPB par-
ticles were suspended in 2 mL PBS, and sealed into a dialy-
sis bag. The dialysis bag was then immersed into 48 mL 
PBS, and stirred for designed time intervals with a magnetic 
stirrer. At each time interval, 1 mL of PBS outside the dial-
ysis bag was taken out from the beaker and the content of 
lamivudine was measured with a UV-vis spectrometer. The 
1 mL of fresh PBS was added to the beaker to keep the con-
stant volume. Each data was averaged from 3 parallel ex-
periments. 
1.4  In vitro cell culture experiments 
(1) Cell culture. HepLL cells are immortalized human liver 
cells [30] which kindly donated by Dr. Jun Li at First Affil-
iated Hospital, Zhejiang University, and cultured with regular 
growth medium consisting of high-glucose DMEM (Gibco) 
containing 100 g/mL streptomycin, 100 U/mL penicillin, 
and 10% fetal bovine serum, and incubated in a 5% CO2 
incubator at 37°C with 100% humidity. 
(2) Cellular uptake of PLGA particles. HepLL cells were 
seeded on a 24-well plate at a density of 5×104 cells per 
well and allowed to attach for 16 h. To determine the parti-
cles uptake rate and amount as a function of incubation time, 
the cells were incubated with 100 g/mL of coumarin-labeled 
PLGA particles for different time. Then the cells were 
washed three times with PBS to remove free PLGA parti-
cles and detached by trypsin. Finally the uptake of coumarin- 
labeled particles was determined by flow cytometry (FACS 
Calibur, Becton Dickinson BD). 
(3) Intracellular distribution. Fluorescent staining of ly-
sosomes, mitochondria, and cell nuclei was carried out and 
confocal laser scanning microscopy (CLSM, LSM 510, Carl 
Zeiss) was used to observe the intracellular distribution of 
PLGA particles. Briefly, after incubation with 100 g/mL 
of Nile red-labeled particles for desired time, the HepLL 
cells were carefully washed with PBS for three times, then 
incubated with LysoTracker® Green and MitoTracker® Green 
at 37°C for 30 min, respectively. Finally the cells were 
stained with DAPI and observed under CLSM. 
(4) Cell viability. The influences of PLGA particles on 
cell viability were assessed using 3-(4,5-dimethylthiazol-2- 
yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, 
104 HepLL cells in 100 L medium were seeded into a well 
of a 96-well plate and incubated overnight. To determine 
the cell viability as a function of particles concentration and 
incubation time, the cells were incubated with various con-
centrations of particles for 24 h and incubated with 100 
g/mL of particles for different time, respectively. After 
removal of the particles, the cells were cultured in fresh 
medium supplemented with 0.5 mg/mL MTT at 37°C for 
another 4 h. The blue crystals generated by the mitochon-
dria dehydrogenase were dissolved with 150 L dimethyl 
sulfoxide (DMSO) and the absorbance at 570 nm was 
measured by a microplate reader (Model 550, Bio-Rad). The 
data was normalized to the particle free control group. 
2  Results and discussion 
2.1  Optimization of fabrication parameters 
The LPB particles were prepared by a W/O/W double 
emulsion-solvent evaporation method. The particle size and 
the drug loading and entrapment efficiency of LPB particles 
were influenced by parameters such as the volume of inner 
aqueous phase and organic phase, concentration of organic 
phase, ultrasonication time, and so on [31]. 
(1) Effect of volume of inner aqueous phase. Firstly, in-
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fluence of the volume of inner aqueous phase on the physi-
ochemical properties of the as-prepared PLGA particles in 
terms of particle size, surface charge, drug loading and en-
trapment efficiency was investigated. Table 1 shows no 
significant change in the particle size along with increase of 
the volume of inner aqueous phase when it was below 0.3 
mL. However, the particle size significantly increased with 
further increase of the volume, which should be resulted 
from the less stable W/O emulsion and thereby the coales-
cence of suspended droplets. Meanwhile, the drug loading 
and entrapment efficiency increased with the volume of the 
inner aqueous phase, reached 1.92% and 40.35% for the 
batch with 0.4 mL internal aqueous phase, respectively. The 
surface zeta potential was around 30 mV due to the ad-
sorption of negatively charged BSA and not obviously in-
fluenced by the polymer concentration. Considering the 
balance between the particle size and the drug encapsulation 
efficiency, 0.3 mL inner aqueous phase was used for the 
following experiments.  
(2) Effect of the PLGA concentration of organic phase. 
The influence of PLGA concentration in organic phase on 
the particle size and drug loading and encapsulation effi-
ciency was then evaluated. The results are summarized in 
Table 2. As the concentration of polymer increased from 
2% to 8%, the particle diameter increased from 257 to 567 
nm. It can be explained by enhancement of viscosity of the 
PLGA solution at higher concentration, leading to poorer 
dispersion. On the other hand, with the increase of the 
PLGA concentration in the oil phase, the drug encapsulation 
efficiency decreased from 34.9% to 24.4%, and the drug 
loading efficiency decreased as well from 1.66% to 1.16%. 
The surface charge property was not obviously influenced 
by the volume of inner aqueous phase.  
(3) Effect of ultrasonication time. During preparation of 
particles with the double emulsion method, the second 
emulsification critically influences the particle size. Hence, 
the intensity and time of emulsification need to be finely 
tuned. The particle size and drug loading efficiency as a 
function of ultrasonication time are summarized in Table 3. 
With the increase of the ultrasonication time, the particle 
size decreased remarkably in the first 40 s, i.e. from 380 to 
280 nm, and then reached a plateau. Meanwhile, both the 
drug loading efficiency (from 0.68% at 10 s to 1.68% at 60 s) 
and drug entrapment efficiency (from 13% at 10 s to ~35% 
at 60 s) were sharply improved at longer ultrasonication 
time, and then leveled off at still longer time. Therefore, 60 s 
would be necessary to form well dispersed emulsion, pre-
venting droplet coalescence during the second emulsion 
process and subsequent drug leakage into the outer aqueous 
phase. Surface zeta potential of the particles was almost 
constant in the experiments, suggesting that the surface 
charge property of the particles mainly depends on the se-
lected macromolecular surfactant instead of the preparation 
parameters. 
Taking all the results into consideration, the optimal fab-
rication conditions are 0.3 mL of inner aqueous phase, 2% 
(w/v) PLGA in dichloromethane and double-60 s ultrasoni-
cation.  
2.2  Characterization of LPB nanoparticles 
The morphology of the LPB particles was characterized by 
SEM and TEM (Figure 2). The LPB particles show a spher-
ical morphology with relative narrow size distribution and  
Table 1  Influence of volume of inner aqueous phase on particle size, surface charge and drug loading (DL) and entrapment efficiency (EE) of the LPB 
particlesa) 
Volume of inner phase (mL) Size (nm) Zeta potential (mV) DL (%) EE (%) 
0.1 249±35 31.0±2.5 0.75±0.10 15.8±2.2 
0.2 260±47 32.3±0.9 1.32±0.08 27.3±1.7 
0.3 257±27 29.3±4.2 1.66±0.23 34.9±4.8 
0.4 384±68 34.2±3.4 1.92+0.28 40.4±5.9 
a) All batches were emulsified using an ultrasonicator (6 W) for 60 s. The 1 mL PLGA dichloromethane solution (2% (w/v), oil phase) was employed. 
The volume of the BSA aqueous solution (3% (w/v), external aqueous phase) was 4 mL.  
Table 2  Influence of concentration of organic phase on particle size, surface charge and drug loading and entrapment efficiency of the LPB particlesa) 
Concentration of the  
organic phase (%, w/v) 
Size (nm) Zeta potential (mV) DL (%) EE (%) 
2 257±27 29.3±4.2 1.66±0.23 34.9±4.8 
4 391±21 28.6±3.7 1.43±0.31 30.0±6.5 
6 496±25 30.5±1.8 1.30±0.16 27.3±3.4 
8 567±35 32.0±1.9 1.16±0.21 24.4±4.4 
a) All batches were emulsified using an ultrasonicator (6 W) for 60 s. The 0.3 mL lamivudine aqueous solution (10 mg/mL, internal aqueous phase) was 
employed. The volume of the BSA aqueous solution (3% (w/v), external aqueous phase) was 4 mL.  
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Table 3  Influence of ultrasonication time on particle size, surface charge and drug loading and entrapment efficiency of the LPB particlesa) 
Ultrasonication time (s) Size (nm) Zeta potential (mV) DL (%) EE (%) 
10 382±38 28.6±5.2 0.62±0.38 13±8 
20 341±26 31.7±4.2 0.80±0.29 16.8±6.1 
30 315±35 26.8±3.3 0.78±0.24 16.4±5 
40 280±14 30.5±3.0 1.23±0.17 25.8±3.6 
50 275±25 32.9±3.7 1.52±0.14 31.9±2.9 
60 257±27 29.3±4.2 1.66±0.23 34.9±4.8 
90 265±19 27.9±2.8 1.61±0.26 33.8±5.5 
120 248±21 28.5±3.6 1.68±0.13 35.3±2.7 
a) All batches were emulsified using an ultrasonicator (6 W) for desired time. The 0.3 mL 10 mg/mL lamivudine aqueous solution and 1 mL 2% (w/v) 
PLGA dichloromethane solution were employed as internal aqueous phase and oil phase, respectively. The volume of the BSA aqueous solution (3% (w/v), 
external aqueous phase) was 4 mL.  
 
Figure 2  SEM (a) and TEM (b) images of LPB particles.  
good dispersity (Figure 2(a)). As shown in Figure 2(b), a 
thick shell was found around the LPB particles, confirming 
the existence of BSA layers. According to the results of 
BCA assay, 58 mg BSA was present on/in 1 g LPB particles. 
The average diameter of the LPB particles was 257 nm in 
the wet state (as measured by DLS) and 212 nm in the dry 
state (as measured by TEM and image-analysis software). 
The difference of the measured size is attributed to the hy-
drophilic BSA molecules on the particle surface. Further-
more, the surface zeta potentials of the LPB particles in 10 
mmol/L NaCl solution was 29.3±4.2 mV, which was im-
proved to 10.9±2.4 mV in cell culture medium with 10% 
FCS due to adsorption of serum proteins. 
2.3  Drug release in vitro 
The release behavior of lamivudine from the LPB particles 
was characterized in PBS with different pH values to mimic 
physiological and intra-lysosome environment at 37°C 
(Figure 3). At pH 7.4, an obvious burst release was ob-
served during the first 2 h, and then the release was slowed 
down and reached to a plateau after 8 h, during which about 
60% of the drug was released. The burst effect is caused by 
lamivudine molecules adsorbed or located near the particle  
 
Figure 3  Release profile of lamivudine from LPB particles at 37°C in 
different mediums. 
surface. At pH 5.5 (similar as in lysosomes), the release 
became faster, and more than 60% of the drug was released 
at first 4 h. The release became much slower afterwards and 
reached a plateau after 48 h, during which 90% of the en-
capsulated lamivudine was released. The faster release in 
acidic environment might be attributed to protonation of the 
amine group in lamivudine, leading to the change of charge 
balance and a larger repulsion between the molecules. Nev-
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ertheless, the LPB particles might protect the encapsulated 
drug in physiological condition and release quickly when 
they are internalized by cells, and particularly transported 
into lysosomes.  
2.4  Cellular uptake 
To make the PLGA particles detectable via fluorescence 
microscopy and flow cytometry, hydrophobic dyes, couma-
rin and Nile red were pre-loaded during the particle fabrica-
tion, respectively. Due to their very poor solubility in aque-
ous medium, no detectable release from the particles was 
found after incubation in the cell culture medium at least for 
24 h at 37°C (data not shown). Loading of the trace amount 
of coumarin/Nile red did not bring significant influences on 
the particle size and morphology as well as surface charge, 
colloidal stability and protein adsorption property. Normal-
ization of the fluorescence intensity of each type of the 
coumarin loaded particles was performed for the quantita-
tive measurements by FCM. To investigate the uptake ki-
netics, the HepLL cells were incubated with 100 g/mL 
coumarin-labeled LPB particles and blank PLGA (PB) par-
ticles for different time intervals, respectively, and then 
quantified with FCM by determining the green fluores-
cence-emitting cells (Figure 4). For the FCM study, the 
logarithmic fluorescence intensity of particle-free control 
cells was set below 10. Therefore, the cells possessing fluo-
rescence intensity larger than 10 were considered as positive 
ones [32,33]. As shown in Figure 4, the cellular uptake 
amount of both particles monotonously increased along 
with the prolongation of the culture time. For both types of 
the particles, the fluorescence intensity was already quite 
high after incubation for 4 h, indicating that internalization 
of both types of PLGA particles is very fast. During the next 
20 h, the fluorescence intensity increased monotonously, 
and then leveled off, revealing that the uptake process was 
completed in 24 h. There is no significant difference in the 
uptake kinetics between the two types of particles, suggesting  
 
Figure 4  Uptake of LPB particles by HepLL cells as a function of culture 
time with a particle concentration of 100 µg/mL. Data was measured by 
flow cytometry and averaged to each cell. 
the encapsulation of lamivudine does not influence on the 
cellular uptake process.  
2.5  Intracellular distribution 
During the process of cellular uptake, the exogenous parti-
cles are initially enclosed into endosomes, which mature 
into multivesicular bodies or late endosomes and eventually 
fuse with lysosomes [34]. Mitochondria are important in-
tracellular energy metabolism places, and are closely related 
to the signals which induce cell apoptosis. The internaliza-
tion process and the cellular distribution of the Nile red- 
labeled LPB particles were microscopically monitored by 
staining the lysosomal compartments with LysoTracker 
Green, the mitochondria with MitoTracker Green, and the 
cell nuclei with DAPI, respectively. Figure 5 shows that 
some LPB particles were internalized after 12 h incubation 
and further increased after 24 h. Only a few particles could 
be observed and colocalized with lysosomes after 12 h in-
cubation. After 24 h incubation, more LPB particles were 
overlapped with lysosomes (yellow) while many LPB parti-
cles were located in the cytoplasm (red) rather than lyso-
somes. This result implies that many LPB particles can es-
cape from the lysosomes. Although many particles were 
found around nucleus, no colocalization signals of the parti-
cles and cell nucleus could be found even after 24 h co- 
incubation, suggesting that the particles could not penetrate 
into cell nucleus.  
As shown in Figure 6, very a few Nile red-labeled LPB 
particles overlapped with the mitochondria after 12 h incu-
bation. When the incubation time was extended to 24 h, a 
few LPB particles were colocalized with the mitochondria, 
indicating the possible interaction of the particles with cell 
organelles such as mitochondria.  
2.6  Cytotoxicity 
MTT assay was used to assess the viability of the HepLL 
cells after incubation with various concentrations of PB and 
LPB particles for 24 h and incubated with 100 g/mL of 
particles for different time, respectively. Figure 7(a) shows 
that in general the cell viability was largely maintained after 
incubation with both types of particles. The cell viability 
slightly decreased along with the increase of particles con-
centration, which decreased to 79.2% and 81.3% of particles 
free controls when the cells were exposed to 200 μg/mL 
PLGA-BSA (PB) and LPB particles, the highest concentra-
tion tested. As shown in Figure 7(b), both PB and LPB par-
ticles showed very low cytotoxicity to HepLL cells during 
the 48 h culture period. Thus, LPB particles are considered 
to be safe as potential drug carriers and encapsulation of 
lamivudine does not bring additional toxicity to normal cells. 
In next step, the cell model with hepatitis B virus infection 
would be created and the anti-virus effect of the LPB parti-
cles would be studied to elucidate the potential application  
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Figure 5  CLSM images of HepLL cells incubated with 100 g/mL LPB particles for 12 h (a) or 24 h (b), respectively. The cell nuclei were stained by 
DAPI (a1, b1), the lysosomes were stained by LysoTracker (a2, b2) and the LPB particles were labeled by Nile red (a3, b3). (a4, b4) The merge images of 
nucleus (blue), lysosomes (green) and LPB particles (red). Scale bar: 10 m.  
 
Figure 6  CLSM images of HepLL cells incubated with 100 g/mL LPB particles for 12 h (a) or 24 h (b), respectively. The cell nuclei were stained by 
DAPI (a1, b1), the mitochondria were stained by MitoTracker (a2, b2) and the LPB particles were labeled by Nile red (a3, b3). (a4, b4) The merge images of 
nucleus (blue), mitochondria (green) and LPB particles (red). Scale bar: 10 m.  
of this kind of drug carriers. 
3  Conclusion 
The lamivudine-loaded PLGA particles were prepared by a 
W/O/W double emulsion-solvent evaporation method with 
BSA as macromolecular surfactant. By varying the experi-
mental conditions such as volume of inner aqueous phase, 
concentration of organic phase and sonication parameters, 
the particle size and drug encapsulation efficiency were 
optimized and finally the LPB particles with ~260 nm in 
diameter, ~35% drug loading efficiency and negative sur-
face charge were obtained. The lamivudine inside LPB par-
ticles showed a burst release at beginning and sustained 
release until 24 h in physiological conditions. The release of 
lamivudine from LPB particles was accelerated in acidic 
medium, making the LPB particles potential intelligent in-
tracellular drug carriers. The LPB particles were readily 
internalized into human liver cells within a short time and  
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Figure 7  Relative cell viability after incubation of HepLL cells with the PB or LPB particles as a function of (a) concentration with a culture time of 24 h, 
and (b) culture time with a particle concentration of 100 g/mL.  
increased gradually with the prolongation of incubation. 
After ingested into the cells, the LPB particles would either 
reside within the lysosomes or transfer to cytoplasm, but 
could not enter into the cell nucleus. The cell viability was 
not significantly influenced by the ingestion of the particles 
regardless of lamivudine encapsulation. 
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